当前位置:药药网 / 数据中心 / 生物制药海外临床研究状况
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
标题(英文)
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
条件
Head and Neck Cancer|Head and Neck Neoplasms|Head and Neck Squamous Cell Carcinoma
干预
Biological: Enoblituzumab|Biological: Retifanlimab|Biological: Tebotelimab